- Delivers 11% normalized organic revenue growth and $1.05 Adjusted EPS, driven by strong growth in all business segments and regions including 12% normalized organic growth in CAG Diagnostics recurring revenues
- Catalyst® and hematology instrument placements both increased over 30% in US and international markets - Transition to all-direct sales strategy in the US on track for 100% direct order and fulfillment capability in Q4 - Company announces launch of Catalyst One™, the Company's next generation chemistry analyzer, with customer shipments beginning November 3 - Strong business momentum supports increase in 2014 Adjusted EPS guidance to $3.85 to $3.90 and preliminary 2015 outlook for 13% to 14% normalized organic revenue growth and $4.38 to $4.48 Adjusted EPS WESTBROOK, Maine , Oct.
Independent. Insightful. Trusted. Morningstar provides stock market analysis; equity, mutual fund, and ETF research, ratings, and picks; portfolio tools; and option, hedge fund, IRA, 401k, and 529 plan research. Our reliable data and analysis can help both experienced enthusiasts and newcomers.